| Species Reactivity | Human |
| Clone | 80A8 |
| Source/Isotype | Human IgG1(K214R,D256E,L358M), Kappa |
| Application | Flow cytometry |
| Specificity | Detects GPRC5D |
| Gene | GPRC5D |
| Other Names | G-protein coupled receptor family C group 5 member D |
| Gene ID | 55507 (human) |
| Background | GPRC5D (g protein-coupled receptor class C Group 5member D) is a g protein-coupled orphan receptor that belongs to the 7th transmembrane protein. Expression is limited in normal tissues, usually limited to hair follicles, but specifically high in MM cells. Studies have found that GPRC5D mRNA expression correlates with plasma cell burden and gene aberrations. GPRC5D activates multiple signaling pathways, including those for cell proliferation, survival, and migration, to promote the growth and proliferation of MM cells. GPRC5D has been shown to be expressed on the surface of myeloma cells independently of BCMA and has been identified as an alternative immunotherapy target antigen for this indication. Therefore, targeted therapy against GPRC5D has emerged as a new direction for MM treatment. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | 80A8 |
| Source/Isotype | Human IgG1(K214R,D256E,L358M), Kappa |
| Application | Flow cytometry |
| Specificity | Detects GPRC5D |
| Gene | GPRC5D |
| Other Names | G-protein coupled receptor family C group 5 member D |
| Gene ID | 55507 (human) |
| Background | GPRC5D (g protein-coupled receptor class C Group 5member D) is a g protein-coupled orphan receptor that belongs to the 7th transmembrane protein. Expression is limited in normal tissues, usually limited to hair follicles, but specifically high in MM cells. Studies have found that GPRC5D mRNA expression correlates with plasma cell burden and gene aberrations. GPRC5D activates multiple signaling pathways, including those for cell proliferation, survival, and migration, to promote the growth and proliferation of MM cells. GPRC5D has been shown to be expressed on the surface of myeloma cells independently of BCMA and has been identified as an alternative immunotherapy target antigen for this indication. Therefore, targeted therapy against GPRC5D has emerged as a new direction for MM treatment. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
